PharmaFocus Today – Page 7 – media

Utilizing stem cells to create a new type of vascular graft, the ‘universal life pipeline’, to promote progress in related surgeries

In a study published in the latest issue of Cell Reports Medicine, scientists from the National Primate Research Center in Wisconsin and the University of Wisconsin Madison demonstrated a “universal life pipeline” – a novel small-diameter vascular graft developed using stem cell-derived arterial endothelial cells (AECs). This achievement is of great significance for advancing research in biotechnology and vascular surgery. Blood vessels are known as the “life vessels” of the human body. Currently, synthetic vascular grafts have been widely used for repairing large blood vessels, but for small diameter vessels such as those used in coronary artery bypass surgery, the existing options are very limited. The usual method is to extract blood vessels from other parts of the patient’s body, but this is not only highly invasive, but also limited by the number and quality of available blood vessels, especially when the patient has comorbidities. Another method is to use ...
- Source: drugdu
- 56
- March 14, 2025
Sunshine Novo and Anlong Biotech use small nucleic acid siRNA technology to tackle the development challenges of cardiovascular and cerebrovascular drugs!

Sunshine Novo and Anlong Biotechnology have officially reached a project and strategic cooperation to jointly promote the application of small nucleic acid siRNA technology platform in the field of cardiovascular and cerebrovascular treatment, and develop an innovative small nucleic acid (siRNA) drug in this field. This collaboration will leverage the unique advantages of siRNA technology to address pain points in current disease treatments, provide patients with longer lasting and more convenient treatment options, and promote innovation and development of small nucleic acid drugs in the field of cardiovascular and cerebrovascular chronic disease treatment. Breakthrough advantages of siRNA technology SiRNA technology, as an emerging therapeutic approach, has shown great potential in the field of chronic disease treatment in recent years. SiRNA drugs achieve long-lasting treatment by targeting specific mRNA molecules and inhibiting the expression of disease-related proteins. Compared with traditional daily medication, siRNA drugs can be administered quarterly or semi annually, ...
- Source: drugdu
- 61
- March 14, 2025
single unit price reduction of 91%

In January 2025, the Guizhou Provincial Health Commission officially launched the public bidding process for the Guizhou Provincial Regional Medical Center Equipment Renewal Project (Phase I). The total budget of this project exceeds 578 million yuan, covering CT MRI、 Ultrasound DSA、 There are dozens of categories of medical equipment such as endoscopes and medical linear accelerators. Ultrasound imaging diagnostic equipment has become a key area for procurement cost savings, with the winning bid for the Consona N9T ultrasound single device being only 210000 yuan. Compared to the budgeted price, the cost savings rate is as high as 91.25%. 01. Ultrasound: a key focus of procurement cost savings This public bidding project has undergone strict evaluation and bidding processes. Except for project 10 and project 14, which were disqualified due to reasons, the winning results of the remaining sub projects have been announced recently. It is noteworthy that during the bidding ...
- Source: drugdu
- 65
- March 14, 2025
3.9 billion! Innovative pharmaceutical giants make another breakthrough

On March 9th, Baili Tianheng released the “2025 Plan for Issuing A-shares to Specific Targets”, which showed that the company plans to issue A-shares to specific targets and raise no more than 3.9 billion yuan (including the main amount). After deducting the issuance expenses, the actual raised funds will be used entirely for innovative drug research and development projects. Affected by this news, on March 10th, the stock price of Baili Tianheng rose slightly by 0.97%, closing at 213.05 yuan per share, with a total market value of 85.4 billion yuan. There is nearly 5 billion yuan in cash lying on the account, but it still needs to raise funds through both A-share and Hong Kong stock platforms. This seemingly contradictory capital operation contains the survival rules and strategic ambitions of Chinese innovative pharmaceutical companies in global competition. 1. Five billion yuan in cash is difficult to fill the research ...
- Source: drugdu
- 58
- March 14, 2025
The number of measles cases in Texas, the United States, has increased to 223

On March 11, local time, the Texas Department of State Health Services reported that a measles outbreak occurred in the southern plains of Texas. Since the end of January this year, 223 cases have been found in the state. Among them, 29 patients have been hospitalized and one school-age child has died. The child was not vaccinated and had no known underlying diseases. The report said that because the disease is highly contagious, more cases may occur in the epidemic area and its surrounding communities. The Texas Department of State Health Services is working with local health departments to investigate the epidemic. Measles is an acute rash respiratory infectious disease caused by the measles virus, which is mainly transmitted through respiratory droplets and aerosols. Within one to two weeks after exposure to the virus, the infected person will have symptoms such as high fever, cough, runny nose, red eyes, tears, ...
- Source: drugdu
- 55
- March 14, 2025
Promote the high-quality development of the biopharmaceutical industry in the Chengdu-Chongqing region

Recently, Jiang Lingfeng, deputy to the National People’s Congress and vice chairman of Zhifei Bio, said in an exclusive interview with the Shanghai Securities News that at this year’s National People’s Congress, he made suggestions on topics such as optimizing the ecology and structure of the biopharmaceutical industry. Solve the dilemma of vaccine companies’ difficulty in collecting payments Public data shows that in the first three quarters of 2024, the average accounts receivable turnover days of listed vaccine companies reached 381 days, an increase of more than 60% over 2022, and the accounts receivable of 11 listed vaccine companies accounted for 107% of their revenue. “Vaccine R&D investment is large, the cycle is long, and the risk is high, requiring a large amount of R&D resources. In recent years, the difficulty of vaccine companies in collecting payments has brought huge pressure on the industry’s capital chain, and the industry’s sustainable ...
- Source: drugdu
- 47
- March 14, 2025
“AI+mRNA” tumor vaccine has made progress. SiliDi Pharmaceutical opened more than 7% higher in the morning.

On the morning of March 12, SiliDi Pharmaceutical Co., Ltd. (01244.HK) opened more than 7% higher. As of press time, it rose 3.33%. On the news front, SiliDi Pharmaceutical Co., Ltd. recently announced that its layout of “AI+mRNA” tumor vaccine has made a breakthrough. The company’s key component of lipid nanoparticles (LNP) for nucleic acid drug delivery, ionizable cationic lipids, has recently applied for PCT patents. It is reported that by using AI to design and screen hundreds of lipid compounds, an ionizable cationic lipid research and development platform has been established for different cell types and organ targeting, and the development of self-developed mRNA tumor vaccine projects has been efficiently coordinated, breaking through delivery technology barriers, improving drug targeting, solving problems such as non-specific tissue distribution, and improving drug development efficiency. SiliDi Pharmaceutical Co., Ltd. is an innovative drug company that has entered the commercialization stage and focuses on ...
- Source: drugdu
- 52
- March 14, 2025
Phase III clinical trial of serum-free rabies vaccine of Aimi Vaccine subsidiary was successful

On March 12, Aimi Vaccine (06660) issued an announcement, announcing that its wholly-owned subsidiary Aimi Honor (Ningbo) Biopharmaceutical Co., Ltd. has completed the Phase III clinical trial of serum-free iterative rabies vaccine and obtained the corresponding production license. The vaccine will be submitted for drug registration, marking a major technological breakthrough in the field of rabies vaccines for the company, and is expected to become the world’s first approved serum-free rabies vaccine. According to the results of the completed Phase III clinical study, the vaccine showed good safety, immunogenicity and immune persistence, and has fully met the preset evaluation standards for clinical trials. At present, there is no serum-free rabies vaccine on the market in the world, and the main products sold in the market are serum rabies vaccines. The serum-free iterative rabies vaccine developed by the company does not contain animal serum, which significantly improves safety and reduces the ...
- Source: drugdu
- 51
- March 14, 2025
Aohua Endoscope, Enters the Medical Robot Industry

Recently, Aohua Endoscope has successfully obtained an invention patent authorization called “Endoscope Trolley and Medical Robot”, with patent application number CN202210369876.8. It is reported that this patent effectively reduces the physical exertion of operators through rich operating functions, which will further enhance the company’s technological advantages in the field of soft endoscopes. As a company with over 30 years of development history, Aohua Endoscope’s product layout covers soft mirrors, hard mirrors, and diagnostic and therapeutic consumables. Its diversified layout from upstream to downstream is continuously enhancing its influence in the industry. 01. Obtained patents for endoscope trolleys and medical robots According to the patent abstract, the present invention provides an endoscope trolley and a medical robot. The endoscope trolley comprises a trolley body, a first telescopic arm, and a second telescopic arm. The trolley body comprises a base and a worktable. The worktable is installed on the base in a ...
- Source: drugdu
- 52
- March 13, 2025
The world’s first! One innovative medical device has obtained FDA breakthrough device certification

Recently, NextBioMedical announced that its absorbable embolic microsphere, Nexsphere-F, has been awarded the “Breakthrough Device” designation by the FDA. At present, Nexsphere-F has been approved for CE, and it is worth mentioning that this product is also the only CE approved microsphere for the treatment of musculoskeletal pain embolism. Innovative technology, breaking through traditional boundaries The Nexsphere-F, which was awarded the breakthrough device this time, is an embolic microsphere with a size of 100-300 μ m that can be quickly absorbed by patients. Its indication is for the treatment of knee osteoarthritis pain in patients who do not respond adequately to conservative non pharmacological treatment and/or analgesics. It is worth mentioning that this product integrates innovative absorbable microsphere technology. When Nexsphere-F is delivered to the patient’s target blood vessel through a 1.7Fr microcatheter, the microspheres will absorb water and expand, thereby achieving precise blockage of the target blood vessel and ...
- Source: drugdu
- 56
- March 13, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.